The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Nippon Kayaku Faces Damage Suit over Elplat Patent
Yakult Honsha and Swiss-based Debiopharm International SA said on May 16 that they have filed a lawsuit in Tokyo against Nippon Kayaku, seeking damages over the generic maker’s alleged infringement on their formulation patent for Elplat (oxaliplatin). Yakult Honsha, which…
To read the full story
Related Article
- Nippon Kayaku Notches Top Court Victory for Elplat Damages Suit Too
April 2, 2018
- Nippon Kayaku Prevails in Elplat Damage Suit: High Court
June 30, 2017
- Sawai Prevails in Patent Suit over Elplat
December 26, 2016
- Nichi-Iko Wins Patent Suit over Elplat
November 1, 2016
- Towa Prevails in Patent Suit over Elplat
April 1, 2016
- Debiopharm Wins Elplat Patent Suit against Nippon Kayaku
March 8, 2016
BUSINESS
- AI-Driven Target Discovery Gains Ground among Japanese Pharma: FRONTEO CEO
December 17, 2025
- Enhertu Combo Wins US FDA Nod in 1st-Line HER2 Breast Cancer
December 17, 2025
- Pfizer Releases Nurtec Migraine Drug in Japan
December 17, 2025
- Towa Lifts Atomoxetine Shipment Curbs Across All Strengths
December 17, 2025
- Daiichi Sankyo Targets Cancer Cure with IO-ADC Combo Strategy
December 17, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…